By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies today said that it has acquired certain assets from Perlegen Sciences, which ceased operations late last year.

Australia's Genetic Technologies said that the primary asset it has obtained is Perlegen's BrevaGen breast cancer risk test. In addition, it said that it acquired a suite of granted patents valid to 2022 that augment and extend its current non-coding patent portfolio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.